Takeda Pharmaceutical...and marketing partner Eli Lilly...face a total of $9 billion in punitive damages after a U.S. jury decided that the drug makers hid the cancer risks of their Actos diabetes drug...Takeda on Tuesday said it disagreed with the U.S. verdict by a Louisiana jury and that it would seek to overturn it. Lilly was unavailable for comment...Regulators in France and Germany suspended sales of the drug in 2011, citing cancer risks. The company still faces several thousand more U.S. lawsuits related to Actos...According to the current label for Actos in the U.S., a long-term study of people taking the drug found a significantly higher risk of developing bladder cancer after more than two years of use...[Also refers to Abbott, Merck, TAP Pharmaceuticals (joint venture Abbott Laboratories & Takeda Pharmaceutical), Toyota]